Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g.,, or any website that lists experimental therapies), or use of computational algorithms.

The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s):New Dates October 30, 2017, February 28, 2018, June 26, 2018, October 30, 2018, February 27, 2019, June 26, 2019, October 30, 2019, February 27, 2020, June 26, 2020, and October 30, 2020 ​​​​

PAR-17-465 Expiration Date New Date October 31, 2020 per issuance of NOT-TR-20-025. (Original Expiration Date: September 8, 2020 )

Agency Website

Amount Description

Application budgets need to reflect the actual needs of the proposed project but may not be greater than:

UG3: up to $200,000 direct costs/year

UH3: up to $100,000 direct costs.

Award Project Period:

 UG3: Up to 24 months (adult indications) or 36 months (pediatric indications) may be requested

UH3: Up to 12 months may be requested

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 30, 2020